Zevra Therapeutics
7 Hawkeye Drive
Suite 103
North Liberty
Iowa
52317
United States
Tel: 319-665-2575
Fax: 319-665-2577
Website: http://www.kempharm.com/
Email: info@kempharm.com
239 articles about Zevra Therapeutics
-
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
8/31/2023
Zevra Therapeutics, Inc. and Acer Therapeutics Inc. announced the companies have entered into a definitive agreement pursuant to which Zevra would acquire Acer in a merger transaction having a total potential value for Acer stockholders of up to $91 million.
-
Zevra Therapeutics Reports Corporate Updates and Second Quarter 2023 Financial Results
8/14/2023
Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today provided corporate updates and reported its financial results for the quarter ended June 30, 2023.
-
Zevra Therapeutics Appoints Thomas Anderson to Board of Directors and Announces Retirement of Matthew R. Plooster
8/7/2023
Zevra Therapeutics, a rare disease company melding science, data, and patient need to create transformational therapies for diseases with limited or no treatment options, proudly welcomes Tom Anderson, a highly accomplished biopharma veteran, to its Board of Directors.
-
Zevra Therapeutics to Report Second Quarter 2023 Results on August 14, 2023
8/2/2023
Zevra Therapeutics, Inc. has announced that it will host a conference call and live audio webcast on Monday, August 14, 2023, at 8:30 a.m. ET, to review its corporate and financial results for the second quarter of 2023.
-
Zevra Therapeutics to Participate in the 2023 NNPDF Family Support and Medical Conference
7/19/2023
Zevra Therapeutics, Inc. today announced their support of the upcoming National Niemann-Pick Disease Foundation’s (NNPDF) Family Support and Medical Conference.
-
Zevra Therapeutics to be Added to Russell 2000® and Russell 3000® Indexes Effective June 26, 2023
6/20/2023
Zevra Therapeutics, Inc. announced its expected addition to the broad-market Russell 3000 ® Index and small-cap Russell 2000 ® Index in accordance with the 2023 Russell indexes annual reconstitution.
-
Zevra Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest
6/13/2023
Zevra Therapeutics, Inc., a rare disease therapeutics company, announced executive management will participate in the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest, Tuesday, June 20 through Thursday, June 22, 2023.
-
Zevra Therapeutics Presents Design of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH) at Beyond Sleepy 2023
6/3/2023
Zevra Therapeutics, Inc. will be presented at the Hypersomnia Foundation’s 2023 Beyond Sleepy Conference being held June 2 - 4, 2023, in Indianapolis, IN, for people living with IH, narcolepsy and Kleine-Levin syndrome and their supporters.
-
Zevra Therapeutics Reports Corporate Updates and First Quarter 2023 Financial Results
5/15/2023
Zevra Therapeutics, Inc., a rare disease therapeutics company, provided corporate updates and reported its financial results for the quarter ended March 31, 2023.
-
Zevra Therapeutics will Participate in RBC Capital Markets Global Healthcare Conference on May 16, 2023
5/10/2023
Zevra Therapeutics, Inc. today announced that R. LaDuane Clifton, the Company’s Chief Financial Officer, will present at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 16, 2023, at 3:05 p.m. ET.
-
Zevra Therapeutics to Report First Quarter 2023 Results on May 15, 2023
5/9/2023
Zevra Therapeutics, Inc. has announced that it will host a conference call and live audio webcast on Monday, May 15, 2023, at 4:30 p.m. ET, to review its corporate and financial results for the first quarter of 2023.
-
Zevra Announces Board of Directors and Leadership Changes
5/8/2023
Zevra Therapeutics, Inc. today announced changes to the Company’s Board of Directors (“Board”) and leadership. At the Company’s recent 2023 Annual Meeting of Stockholders (“Annual Meeting”), Zevra shareholders elected John B. Bode, Douglas W. Calder and Corey Watton to Zevra’s Board.
-
Zevra Therapeutics Announces FDA Acceptance of IND Application for KP1077 in Narcolepsy
5/3/2023
Zevra Therapeutics, Inc. today announced the acceptance of an Investigational New Drug (“IND”) application by the U.S. Food and Drug Administration (“FDA”) to begin a Phase 1 clinical trial of KP1077 in narcolepsy which is expected to provide additional information regarding the optimal dosing regimen.
-
Leading Proxy Advisory Firms ISS and Glass Lewis Demonstrate Strong Support for Zevra’s Transformation Strategy
4/17/2023
Zevra Therapeutics, Inc. announced that leading proxy advisory firms Institutional Shareholder Services and Glass Lewis & Co. have voiced their support for Zevra’s nominees and strategy and found that Mangless’ arguments and nominees were not compelling.
-
Zevra Therapeutics Announces Submission of IND for KP1077 in Narcolepsy
4/4/2023
Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (“Zevra” or the “Company” and formerly KemPharm, Inc.), a rare disease therapeutics company, today announced the submission of an Investigational New Drug (IND) application seeking authorization from the U.S. Food and Drug Administration (“FDA”) to begin a Phase 1 clinical trial of KP1077 in narcolepsy.
-
Zevra Therapeutics Appoints Biopharma Veteran Wendy Dixon, Ph.D., to Board of Directors
3/30/2023
Zevra Therapeutics announced that it has appointed Wendy L. Dixon, Ph.D., to the Company’s Board of Directors, effective immediately following the conclusion of the 2023 Annual Meeting of Stockholders, to fill the vacancy resulting from Dr. Travis Mickle’s resignation from the Board effective as of the day of the 2023 Annual Meeting to be held on April 25, 2023.
-
Zevra Therapeutics Announces Collaboration with RARE-X and the Sleep Consortium as Founding Member of New Sleep Data Initiative
3/17/2023
Zevra Therapeutics, Inc. today announced that it has joined the Sleep Data Initiative as a founding member.
-
Zevra Therapeutics Files Definitive Proxy Statement and Mails Letter to Shareholders
3/15/2023
Zevra Therapeutics today announced it has filed its definitive proxy statement with the U.S. Securities and Exchange Commission (the “SEC”) in connection with the Company’s 2023 Annual Meeting of Stockholders (“Annual Meeting”).
-
Zevra Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Corporate Updates
3/7/2023
Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (“Zevra,” or “the Company,” formerly “KemPharm, Inc.”), a rare disease therapeutics company, today reported its financial results for the fourth quarter and year ended December 31, 2022.
-
Zevra Therapeutics to Present at 35th Annual Roth Conference
3/6/2023
Zevra Therapeutics, Inc. today announced that Richard W. Pascoe, the Company’s Chief Executive Officer, will participate in a fireside chat at the 35th Annual Roth Conference on Monday, March 13, 2023, at 2:00 p.m. PT.